AbCellera to Announce Phase 2 Top-Line Data for Menopause Drug ABCL635 on August 10

AbCellera Biologics announced it will release top-line results from its Phase 2 clinical trial for ABCL635, a potential first-in-class treatment for moderate-to-severe vasomotor symptoms (VMS) due to menopause. The data will be released before the market opens on Monday, August 10, 2026, followed by an investor conference call.

Key Details

• Drug Candidate: ABCL635, a non-hormonal antibody drug for treating moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause.
• Event: Release of top-line data from the Phase 2, randomized, double-blind, placebo-controlled trial (NCT07118891).
• Timeline: Data will be released before market open on August 10, 2026, with an investor call scheduled for 7:30 a.m. ET the same day.
• Trial Information: The study enrolled approximately 80 postmenopausal women to evaluate the efficacy of ABCL635 in reducing the frequency and severity of VMS.